Amenamevir
CAS: 841301-32-4
Ref. 3D-RIB30132
5mg | 497,00 € | ||
10mg | 758,00 € | ||
25mg | 1.337,00 € | ||
50mg | 2.140,00 € | ||
100mg | 3.422,00 € |
Información del producto
- N-(2-((4-(1,2,4-Oxadiazol-3-yl)phenyl)amino)-2-oxoethyl)-N-(2,6-dimethylphenyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide
- 2H-Thiopyran-4-carboxamide, N-(2,6-dimethylphenyl)tetrahydro-N-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-, 1,1-dioxide
- N-(2,6-Dimethylphenyl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl] amino}-2-oxoethyl)-1,1-dioxothiane-4-carboxamide
- N-(2,6-Dimethylphenyl)tetrahydro-N-[2-[[4-(1,2,4-oxadiazol-3-yl)phenyl]amino]-2-oxoethyl]-2H-thiopyran-4-carboxamide 1,1-dioxide
- ASP 2151
- Amenamevir(ASP 2151)
- ASP-2151
Amenamevir is a drug used to treat herpes simplex virus (HSV). It is an anti-viral drug that prevents HSV from multiplying. Amenamevir prevents the production of the HSV protein that allows it to attach to and enter human cells. Amenamevir is also active against other viruses, such as hepatitis C and HIV. The chemical structure of amenamevir has been elucidated through X-ray crystallography and nuclear magnetic resonance spectroscopy. Amenamevir has been shown to be effective against HSV-1 in both urine samples and in cell cultures. The antiviral activity of amenamevir may be due to its ability to prevent the virus from attaching itself to a cell's surface, inhibiting viral replication by interfering with the synthesis of viral DNA, or inhibiting the production of proteins essential for assembly of new virus particles.
Amamevir is currently undergoing clinical trials for treatment of hepatic impairment.
Propiedades químicas
Consulta técnica sobre: 3D-RIB30132 Amenamevir
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.